Literature DB >> 11508648

Resveratrol reduction of infarct size in Long-Evans rats subjected to focal cerebral ischemia.

S S Huang1, M C Tsai, C L Chih, L M Hung, S K Tsai.   

Abstract

Resveratrol is found in a wide variety of plant species. It is present in the seeds and skin of grapes and constitutes one of the major components of red wine. This study was undertaken to evaluate whether resveratrol could effectively suppress infarct size from the damaging effects of focal cerebral ischemia. The middle cerebral artery was occluded for 1 hr and 24 hr reperfusion in anesthetized Long-Evans rats. In pretreatment or treatment groups, resveratrol, at dosages of 10(-6), 10(-7), 10(-8) and 10(-9) g/kg, was intravenous injected 15 minutes before middle cerebral artery (MCA) occlusion or when the common carotid arteries clips were removed respectively. Pretreatment or treatment of resveratrol (10(-6), 10(-7), 10(-8) and 10(-9) g/kg) did not produce any changes in pH, blood gases, heart rate or mean arterial blood pressure, but it significantly reduced the total volume of infarction at the doses 10(-6) and 10(-7) g/kg. Our study suggests resveratrol is a potent neuroprotective agent in focal cerebral ischemia. Its beneficial effects may be related to its anti-platelet aggregation activity, vasodilating effect, antioxidant property or by all mechanisms together.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11508648     DOI: 10.1016/s0024-3205(01)01195-x

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  44 in total

Review 1.  Resveratrol neuroprotection in stroke and traumatic CNS injury.

Authors:  Mary S Lopez; Robert J Dempsey; Raghu Vemuganti
Journal:  Neurochem Int       Date:  2015-08-12       Impact factor: 3.921

2.  Evaluation of the neuroprotective effects of citicoline after experimental spinal cord injury: improved behavioral and neuroanatomical recovery.

Authors:  Neslihan Yücel; Süleyman R Cayli; Ozkan Ateş; Neşe Karadağ; Serpil Firat; Yusuf Turköz
Journal:  Neurochem Res       Date:  2006-06-21       Impact factor: 3.996

3.  Viewpoint: mechanisms of action and therapeutic potential of neurohormetic phytochemicals.

Authors:  Mark P Mattson; Tae Gen Son; Simonetta Camandola
Journal:  Dose Response       Date:  2007-08-06       Impact factor: 2.658

4.  Resveratrol alleviates nerve injury after cerebral ischemia and reperfusion in mice by inhibiting inflammation and apoptosis.

Authors:  Liqun Fang; Hongmei Gao; Weina Zhang; Wenjie Zhang; Yanan Wang
Journal:  Int J Clin Exp Med       Date:  2015-03-15

Review 5.  Adaptive cellular stress pathways as therapeutic targets of dietary phytochemicals: focus on the nervous system.

Authors:  Jaewon Lee; Dong-Gyu Jo; Daeui Park; Hae Young Chung; Mark P Mattson
Journal:  Pharmacol Rev       Date:  2014-07       Impact factor: 25.468

Review 6.  Role of angiogenic factors of herbal origin in regulation of molecular pathways that control tumor angiogenesis.

Authors:  Manoj Kumar; Sunil Kumar Dhatwalia; D K Dhawan
Journal:  Tumour Biol       Date:  2016-09-10

7.  Resveratrol preconditioning induces cerebral ischemic tolerance but has minimal effect on cerebral microRNA profiles.

Authors:  Mary S Lopez; Robert J Dempsey; Raghu Vemuganti
Journal:  J Cereb Blood Flow Metab       Date:  2016-06-20       Impact factor: 6.200

8.  Pomegranate polyphenols and resveratrol protect the neonatal brain against hypoxic-ischemic injury.

Authors:  Tim West; Madeliene Atzeva; David M Holtzman
Journal:  Dev Neurosci       Date:  2007       Impact factor: 2.984

9.  Retinal protective effects of resveratrol via modulation of nitric oxide synthase on oxygen-induced retinopathy.

Authors:  Woo Taek Kim; Eok Soo Suh
Journal:  Korean J Ophthalmol       Date:  2010-04-06

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.